Abstract
The global anti-infective market is currently valued at US$66.5 billion with
antiviral agents accounting for 24% of sales (excluding vaccines which target
viral infectious diseases).
According to Arrowhead Publishers' new report The Antivirals Market: R&D
Pipelines, Markey Analysis and Competitive Landscape, the anti-viral
market will be driven by the uptake of newer anti-retroviral agents in
combination therapy and the launch of ten new products for the treatment of
HIV and hepatitis which will address the need of treatment-resistant patients.
This will help to stem the tide of this prevalent and often lethal killer in
our society today.
Pharmaceutical companies continue to develop a new generation of
antiretroviral agents to overcome the issue of drug and cross-resistance.
Meanwhile new drug classes are under evaluation that increases the virologists
armory against these endemic and often deadly infectious diseases.
This report examines each of the antiviral classes in turn, assessing the
market potential and encompassing the major infectious diseases to which they
are applicable.
The following product classes are analyzed in this report:
- antisense
- attachment, entry and fusion inhibitors
- DNA polymerase inhibitors
- integrase inhibitors
- interferons
- maturation inhibitors
- monoclonal antibodies
- neuraminidase inhibitors
- NS3 protease inhibitors
- nucleoside reverse transcriptase inhibitors
- nucleotide reverse transcriptase inhibitors
- protease inhibitors
- reverse transcriptase inhibitors
- RNA polymerase inhibitors
- The report assesses the overall antiviral market, key classes, the drivers
and resistors influencing their prescription. The report provides an overview
of key products in each category, summarizing their clinical efficacy and
marketing position. The overview of the current market is given in terms of
segmentation by category and by leading players, therapies and their products
and analyzes market trends.
The report examines promising pipeline products and their potential impact on
the prescription of current and new antiviral agents and the future antiviral
market.
Key features of this report:
- Overview of the antiviral market, including main infectious agents,
therapeutic drug classes and key players.
- In-depth analysis of different classes of antiviral agents, including key
antiretroviral and antiviral agents and compares drugs within each class.
- Comprehensive facts and figures for the antiviral market, including main
players and therapeutic break-downs.
- Future trends in the antiviral marketplace, driven by drug resistance,
cross-resistance and patient demographics.
- Outlook for the antiviral market, including the emergence of novel
therapies, new combination therapies and the impact of generics.
View Cart
